The projected value of complement inhibitors market is expected to be valued at USD 6,800 million in 2022 and is anticipated to grow at a CAGR of 15% during the forecast period 2022-2035.

Since the approval of Soliris? in 2007, the landscape of complement drug discovery has garnered substantial attention within the medical and pharmaceutical communities. Presently, there are nine commercially available complement therapeutics, with an impressive pipeline of approximately 190 molecules in various stages of development across diverse disease indications. Noteworthy among these are Berinert?, Cinryze?, ORLADEYO?, Ruconest?, and TAKHZYRO?, all having received approval from both the US FDA and the EMA for the treatment of hereditary angioedema. In a groundbreaking development, the FDA has granted approval for EMPAVELITM (pegcetacoplan), a pioneering complement C3 inhibitor developed by Apellis Pharmaceuticals, specifically for paroxysmal nocturnal hemoglobinuria. This marks a significant stride forward, presenting potential applications in autoimmune and inflammatory disorders, and emphasizes the expanding scope of complement-targeted therapeutic interventions.

The complement system, elucidated in the 19th century, stands as a pivotal component of the innate immune system and tissue homeostasis. Its role in regulating cell survival and pathogen elimination is crucial. Dysregulation in complement activation can lead to various diseases, catalyzing the development of complement-targeted therapeutics aimed at inhibiting activation, thereby mitigating tissue inflammation and modulating the adaptive immune response. The ongoing research in this arena is concentrating on the next generation of complement therapeutics, encompassing biologics, gene therapies, oligonucleotides, small interfering RNAs, and small molecule-based options, each tailored to address specific disease conditions.

As a multifaceted innate immune surveillance system, the complement system presents a rich field for uncovering novel therapeutic targets in the future. Research endeavors in this domain, bolstered by grants totaling USD 837 million from the National Institutes of Health, are propelling advancements. The active participation of both established pharmaceutical companies and new entrants underscores the dynamism of the complement therapeutics market, positioning it for consistent growth. The optimism in the field is further fueled by encouraging clinical research, a broadened disease focus, and innovative approaches extending beyond C5. These efforts not only aim to decrease costs but also address safety concerns, thereby molding the complement therapeutics landscape in the years ahead. The future holds promise for a comprehensive transformation in the understanding and treatment of diseases through the continued evolution of complement-targeted therapies.

Research Coverage
? A comprehensive overview of the complement system, detailing immune cells, key proteins, activation pathways, consequences of dysregulation, types of complement therapeutics, limitations, and the future landscape.
? An analysis of the current market landscape for next generation complement therapeutics, considering parameters like development status, molecule type, biological target, pathway, mechanism of action, disease indication, therapeutic area, administration route, and therapy type.
? A detailed profiles of major players in next generation complement therapeutics development, featuring company overviews, financial information, product portfolios, recent developments, and future outlooks.
? Over 870 clinical studies of next generation complement therapeutics, covering trial status, registration year, phase, patient population, sponsor type, study type, design, industry/non-industry players, indications, drug types, focus areas, and regional distribution.
? Over 1,450 scientific articles on next generation complement therapeutics, exploring publication years, focus areas, top authors, research journals, indications, and therapeutic areas.
? Grants awarded for next generation complement therapeutics research from 2017-2021, considering parameters like year, amount, funding institute, support period, grant type, activity code, recipient organizations, NIH departments, study sections, focus areas, program officers, and locations.
? An in-depth analysis of patents filed/granted for next generation complement therapeutics between 2016-2021, covering publication year, patent type, location, CPC symbols, applicant type, patent age, focus areas, leading players, characteristics, benchmarking, and valuation.
? Detailed partnerships in the domain, encompassing clinical trials, distribution, licensing, product development, manufacturing agreements, research, and development agreements, and other relevant deals.
? List of funding and investments since 2014, including venture capital financing, secondary offerings, private placements, grants, debt financing, and other equity in companies focusing on next generation complement therapeutics.
? Detailed analysis of big pharma players in the field, using spider web, Harvey ball, and wind rose chart analyses based on parameters like therapeutics under development, molecule type, development status, therapeutic areas, partnerships, patents, and years of experience.
? A detailed market forecast analysis, projecting the future potential of the next generation complement therapeutics market until 2035. It includes sales projections segmented by target disease indications, therapeutic areas, molecule type, target pathway, therapy type, administration route, and geographical regions.

Key Market Companies
? Amgen
? CSL Behring
? Innovent Biologics
? Novartis
? Regeneron
? Roche
? Sanofi
? Takeda
? UCB